Treatment for gliomas can involve surgery, radiation therapy, and chemotherapy, as well as a range of supportive treatments.| Rare Cancer News
Kite Pharma has initiated a global Phase 3 trial to test the CAR T-cell therapy anito-cel in relapsed or refractory multiple myeloma.| Rare Cancer News
About 15% relapsed in the first year and patients lived a median of 7.5 years, and without disease progression for a median of three years.| Rare Cancer News